Cogent Biosciences, Inc. — Director's Dealing 2018

Mar 29, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Unum Therapeutics, Inc. (UMRX)
CIK: 0001622229
Period of Report: 2018-03-28

Reporting Person: Booth Bruce (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (3184446)		Indirect
Series B Preferred Stock	$		Common Stock (83037)		Indirect

Footnotes

F1: Each share is convertible on a 1.5701314513884-for-1 basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The shares have no expiration date.

F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Booth is a member of AVA IX LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund IX, except to the extent of his pecuniary interest therein, if any.